Akebia Therapeutics (AKBA) Cash from Investing Activities (2013 - 2026)
Akebia Therapeutics' (AKBA) quarterly Cash from Investing Activities came in at -$62000.0 in Q1 2026, down 140.26% year-on-year from $154000.0 in Q1 2025, and up 99.21% on a QoQ basis from -$7.9 million in Q4 2025.
Akebia Therapeutics (AKBA) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 13 years of Cash from Investing Activities data on file, last reported at -$62000.0 in Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 140.26% year-over-year to -$62000.0 in Q1 2026; TTM through Mar 2026 was -$8.1 million, a 6828.93% decrease from a year earlier, with the FY2025 full-year figure at -$7.9 million, down 23918.18% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$62000.0, up from -$7.9 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for AKBA reached as high as $154000.0 in Q1 2025 and fell as low as -$7.9 million in Q4 2025.
- Historically, Cash from Investing Activities has averaged -$903888.9 across 4 years, with a median of -$62000.0 in 2026.
- Across the five-year window, Cash from Investing Activities slumped 100.57% in 2022 and sank 393750.0% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at -$114000.0 in 2022, then soared by 98.25% to -$2000.0 in 2024, then sank by 393750.0% to -$7.9 million in 2025, then jumped by 99.21% to -$62000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$62000.0 in Q1 2026, -$7.9 million in Q4 2025, and -$77000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.96 Bn | 32.22 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Akebia Therapeutics | 341.82 Mn | 179.22 Mn | 41.25 Mn | -62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | -7.88 Mn |
| Dec 31, 2025 | -7.88 Mn |
| Sep 30, 2025 | -77,000.00 |
| Sep 30, 2025 | -77,000.00 |
| Jun 30, 2025 | -126,000.00 |
| Jun 30, 2025 | -126,000.00 |
| Mar 31, 2025 | 154,000.00 |
| Mar 31, 2025 | 154,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Mar 31, 2022 | -114,000.00 |
| Mar 31, 2022 | -114,000.00 |
| Jun 30, 2021 | 20.00 Mn |
| Jun 30, 2021 | 20.00 Mn |